Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Rinke A, et al. Among authors: blaker m. J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24. J Clin Oncol. 2009. PMID: 19704057 Clinical Trial.
Effects of two instrument-generation changes on adenoma detection rate during screening colonoscopy: results from a prospective randomized comparative study.
Zimmermann-Fraedrich K, Groth S, Sehner S, Schubert S, Aschenbeck J, Mayr M, Aminalai A, Schröder A, Bruhn JP, Bläker M, Rösch T, Schachschal G. Zimmermann-Fraedrich K, et al. Among authors: blaker m. Endoscopy. 2018 Sep;50(9):878-885. doi: 10.1055/a-0607-2636. Epub 2018 Jul 23. Endoscopy. 2018. PMID: 30036893 Clinical Trial.
Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer.
Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, Castaños-Vélez E, Blumenstein BA, Rösch T, Osborn N, Snover D, Day RW, Ransohoff DF; PRESEPT Clinical Study Steering Committee, Investigators and Study Team. Church TR, et al. Gut. 2014 Feb;63(2):317-25. doi: 10.1136/gutjnl-2012-304149. Epub 2013 Feb 13. Gut. 2014. PMID: 23408352 Free PMC article.
Efficacy and safety of PICOPREP tailored dosing compared with PICOPREP day-before dosing for colon cleansing: a multi-centric randomised study.
Kiesslich R, Schubert S, Mross M, Klugmann T, Klemt-Kropp M, Behnken I, Bonnaud G, Keulen E, Groenen M, Blaker M, Ponchon T, Landry W, Stoltenberg M. Kiesslich R, et al. Among authors: blaker m. Endosc Int Open. 2017 Apr;5(4):E282-E290. doi: 10.1055/s-0043-102433. Endosc Int Open. 2017. PMID: 28393103 Free PMC article.
Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2).
Kucharzik T, Dignass A, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengiesser K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators. Kucharzik T, et al. Z Gastroenterol. 2024 May;62(5):769-858. doi: 10.1055/a-2271-0994. Epub 2024 May 8. Z Gastroenterol. 2024. PMID: 38718808 Free article. German. No abstract available.
[Update: Addendum to S3-Guidelines Crohn disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease with regard to COVID-19 (version 2.0)].
Schmidt C, Stallmach A, Sturm A, Bachmann O, Helwig U, Koletzko S, Lynen P, Schnoy E, Dignass A, Kucharzik T, Blumenstein I; Collaborators. Schmidt C, et al. Z Gastroenterol. 2024 Apr;62(4):517-534. doi: 10.1055/a-2255-7184. Epub 2024 Apr 10. Z Gastroenterol. 2024. PMID: 38599579 German. No abstract available.
Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1) – Februar 2023 – AWMF-Registriernummer: 021-009.
Kucharzik T, Dignass A, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengiesser K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Kucharzik T, et al. Z Gastroenterol. 2023 Aug;61(8):1046-1134. doi: 10.1055/a-2060-0935. Epub 2023 Aug 14. Z Gastroenterol. 2023. PMID: 37579791 Free article. German. No abstract available.
Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004.
Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators:. Sturm A, et al. Z Gastroenterol. 2022 Mar;60(3):332-418. doi: 10.1055/a-1713-3941. Epub 2022 Mar 9. Z Gastroenterol. 2022. PMID: 35263784 German. No abstract available.
Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany.
Teich N, Bläker M, Holtkamp-Endemann F, Jörgensen E, Stallmach A, Hohenberger S. Teich N, et al. Among authors: blaker m. Inflamm Intest Dis. 2021 Feb;6(1):48-60. doi: 10.1159/000512159. Epub 2020 Dec 18. Inflamm Intest Dis. 2021. PMID: 33850839 Free PMC article.
37 results